The druggable genome
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
An assessment of the number of molecular targets that represent an opportunity for therapeutic intervention is crucial to the development of post-genomic research strategies within the pharmaceutical industry. Now that we know the size of the human genome, it is interesting to consider just how many molecular targets this opportunity represents. We start from the position that we understand the properties that are required for a good drug, and therefore must be able to understand what makes a good drug target.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The dataset adds high-quality structural models across a broad range of Gene Ontology (GO) terms36,37, including pharmaceutically relevant classes such as enzymes and membrane proteins38 (Fig. 1d).”
From Highly accurate protein structure prediction for the human proteome (2021) · cites this paper as [38]
In the citing paper
“Proteins have several additional advantages as they are most often the direct mediators of biological processes and form the vast majority of currently druggable targets in disease160.”
From Measuring biological age using omics data (2022) · cites this paper as [160]
In the citing paper
“Only around 20% of the human proteome is considered to be druggable with small-molecule antagonists.”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [2]
In the citing paper
“Although this has been a highly effective approach, it has left potential drug targets undrugged or underdrugged45.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [45]
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,760 · cited 1×
“identified 483 targets, and concluded that there could be 5,000–10,000 potential targets on the basis of an estimate of the number of disease-related gene”
BackgroundMetabolite profiling for plant functional genomics
Fiehn, O., Kopka, J., Dörmann, P., Altmann, T., Trethewey, R. N., & Willmitzer, L. (2000) · Nature Biotechnology · doi:10.1038/81137 · Cited by 2,127 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
BackgroundComparative Genomics of the Eukaryotes
Rubin, G. M., Yandell, M. D., Wortman, J. R., Gabor, G. L., Miklos, Nelson, C. R., Hariharan, I. K., Fortini, M. E., Li, P. W., Apweiler, R., et al. (2000) · Science · doi:10.1126/science.287.5461.2204 · Cited by 1,698
Apweiler, R. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.37 · Cited by 1,079
A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations
Raamsdonk, L. M., Teusink, B., Broadhurst, D., Zhang, N., Hayes, A., Walsh, M. C., Berden, J. A., Brindle, K. M., Kell, D. B., Rowland, J. J., et al. (2001) · Nature Biotechnology · doi:10.1038/83496 · Cited by 1,005 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
BackgroundTweeddale, H., Notley-McRobb, L., & Ferenci, T. (1998) · Journal of Bacteriology · doi:10.1128/jb.180.19.5109-5116.1998 · Cited by 393 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
Background
Cited by
Items 301–400 of 1,029
Engineering G protein-coupled receptors to facilitate their structure determination
Tate, C. G., & Schertler, G. F. (2009) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2009.07.004 · Cited by 171
cAMP detection methods in HTS: selecting the best from the rest
Williams, C. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1306 · Cited by 170
“Analysis has indicated that ∼45% of currently marketed medicines are targeted to receptors and that they represent one of the largest druggable gene familie”
BackgroundNew insights from structural biology into the druggability of G protein-coupled receptors
Mason, J. S., Bortolato, A., Congreve, M., & Marshall, F. H. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.02.005 · Cited by 170
Chris Lipinski discusses life and chemistry after the Rule of Five
Owens, J. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02556-4 · Cited by 171
Phosphorylation of Threonine 3
Aiken, C. T., Steffan, J. S., Guerrero, C. M., Khashwji, H., Lukacsovich, T., Simmons, D., Purcell, J. M., Menhaji, K., Zhu, Y.-Z., Green, K., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.013193 · Cited by 171
The genetics of asthma and the promise of genomics-guided drug target discovery
El-Husseini, Z. W., Gosens, R., Dekker, F., & Koppelman, G. H. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30363-5 · Cited by 161
Embryonic stem cells in drug discovery
McNeish, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1281 · Cited by 165
“The race now is to understand the chemically druggable target space of the human genome, which is apparently shrinking rapidl”
BackgroundStable RNA interference rules for silencing
Fellmann, C., & Lowe, S. W. (2014) · Nature Cell Biology · doi:10.1038/ncb2895 · Cited by 163
“of three large categories: (1) sequence-based homology with non-target transcripts; (2) aberrant miRNA biogenesis of endogenous or exogenous”
BackgroundComputational design of peptide ligands
Vanhee, P., van der Sloot, A. M., Verschueren, E., Serrano, L., Rousseau, F., & Schymkowitz, J. (2011) · Trends in Biotechnology · doi:10.1016/j.tibtech.2011.01.004 · Cited by 166
Novel designer receptors to probe GPCR signaling and physiology
Wess, J., Nakajima, K., & Jain, S. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.006 · Cited by 156
“As a result, GPCRs are the target of a very large number of drugs in current clinical use [1].”
BackgroundBiological targets and mechanisms of action of natural products from marine cyanobacteria
Salvador-Reyes, L. A., & Luesch, H. (2015) · Natural Product Reports · doi:10.1039/c4np00104d · Cited by 162
Using positron emission tomography to facilitate CNS drug development
Lee, C.-M., & Farde, L. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.04.004 · Cited by 168
Oligonucleotide Therapeutics: From Discovery and Development to Patentability
Moumné, L., Marie, A.-C., & Crouvezier, N. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020260 · Cited by 158
“Although membrane receptors and enzymes are classically the targets of small molecules, and extracellular proteins or membrane receptors can be modulated with monoclonal antibodies, certain types of proteins such as structural proteins or transcription factors are generally hardly “druggable” [1].”
BackgroundBakan, A., Nevins, N., Lakdawala, A. S., & Bahar, I. (2012) · Journal of Chemical Theory and Computation · doi:10.1021/ct300117j · Cited by 168
Stitched α-Helical Peptides via Bis Ring-Closing Metathesis
Hilinski, G. J., Kim, Y.-W., Hong, J., Kutchukian, P. S., Crenshaw, C. M., Berkovitch, S. S., Chang, A., Ham, S., & Verdine, G. L. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505141j · Cited by 164
Allosteric modulation of heterodimeric G-protein-coupled receptors
Milligan, G., & Smith, N. J. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.11.001 · Cited by 162
The Human Platelet Membrane Proteome Reveals Several New Potential Membrane Proteins
Moebius, J., Zahedi, R. P., Lewandrowski, U., Berger, C., Walter, U., & Sickmann, A. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500209-mcp200 · Cited by 167
“membrane receptors as well as other membrane proteins (3).”
BackgroundSingle‐cell analysis of population context advances RNAi screening at multiple levels
Snijder, B., Sacher, R., Rämö, P., Liberali, P., Mench, K., Wolfrum, N., Burleigh, L., Scott, C. C., Verheije, M. H., Mercer, J., et al. (2012) · Molecular Systems Biology · doi:10.1038/msb.2012.9 · Cited by 169
“For the 34 small-scale screens, we selected a set of 49 human kinases that were previously implicated in virus infection and endocytosis (Supplementary Table 1) (Pelkmans et al, 2005), while the large-scale screens were performed on 6978 human genes constituting the druggable genome (Hopkins and Groom, 2002).”
Wood, A., & Armour, D. (2005) · Progress in Medicinal Chemistry · doi:10.1016/s0079-6468(05)43007-6 · Cited by 161
Small-molecule inhibitors targeting G-protein–coupled Rho guanine nucleotide exchange factors
Shang, X., Marchioni, F., Evelyn, C. R., Sipes, N., Zhou, X., Seibel, W., Wortman, M., & Zheng, Y. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1212324110 · Cited by 157
Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery
M. Scott, L., R. Lawrence, H., M. Sebti, S., J. Lawrence, N., & Wu, J. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791209027 · Cited by 156
Structure-Based Drug Design Strategies in Medicinal Chemistry
Andricopulo, A., Salum, L., & Abraham, D. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789207127 · Cited by 161
“The understanding of the structural and chemical binding properties of important drug targets in biologically relevant pathways allows the design of small molecules capable of regulating or modulating specific target functions in the body that are closely linked to human diseases and disorders, through multiple interm…”
BackgroundScaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective
Zhao, H. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.12.003 · Cited by 159
Size-Specific Ligands for RNA Hairpin Loops
Thomas, J. R., Liu, X., & Hergenrother, P. J. (2005) · Journal of the American Chemical Society · doi:10.1021/ja051685b · Cited by 160
Managing drug resistance in cancer: lessons from HIV therapy
Bock, C., & Lengauer, T. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3297 · Cited by 170
Towards Accurate Free Energy Calculations in Ligand Protein-Binding Studies
Steinbrecher, T. B., & Labahn, A. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790514453 · Cited by 184
“de [6].”
Identification of Attractive Drug Targets in Neglected-Disease Pathogens Using an In Silico Approach
Crowther, G. J., Shanmugam, D., Carmona, S. J., Doyle, M., Hertz‐Fowler, C., Berriman, M., Nwaka, S., Ralph, S. A., Roos, D. S., Voorhis, W. C. V., et al. (2010) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0000804 · Cited by 159
“also took a distinct approach to druggability, rewarding proteins with domains targeted by compounds obeying the Lipinski ‘‘Rule of 5’’ [51] and having EC numbers associated with druggability.”
BackgroundSmall molecule recognition of disease-relevant RNA structures
Meyer, S. M., Williams, C. C., Akahori, Y., Tanaka, T., Aikawa, H., Tong, Y., Childs-Disney, J. L., & Disney, M. D. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00560f · Cited by 160
Sabbadin, D., & Moro, S. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci400766b · Cited by 173
Where is the hope for drug discovery? Let history tell the future
De, K., Li, X., & Zhang, H. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.07.002 · Cited by 179
Novel Peptide Therapeutic Approaches for Cancer Treatment
Li, C. M., Haratipour, P., Lingeman, R. G., Perry, J. J. P., Gu, L., Hickey, R. J., & Malkas, L. H. (2021) · Cells · doi:10.3390/cells10112908 · Cited by 167
“The majority of modern drug development efforts focus on a small group of 3000 druggable protein targets consisting of kinases and other enzymes, G proteincoupled receptors, ion channels, and nuclear hormone receptors [1].”
BackgroundInvestigation of stable and transient protein–protein interactions: Past, present, and future
Wetie, A. G. N., Sokolowska, I., Woods, A. G., Roy, U., Loo, J. A., & Darie, C. C. (2013) · PROTEOMICS · doi:10.1002/pmic.201200328 · Cited by 174
“Membrane proteins represents 60% of the known existing and future drug targets [169].”
BackgroundPrioritizing Genomic Drug Targets in Pathogens: Application to Mycobacterium tuberculosis
Hasan, S., Daugelat, S., Rao, P. S. S., & Schreiber, M. (2006) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0020061 · Cited by 159
“The M. tuberculosis proteome was scanned for LR5- druggable Interpro domains, and 354 such targets were Figure 1.”
BackgroundInfluential“Molecular Switches” on mGluR Allosteric Ligands That Modulate Modes of Pharmacology
Wood, M. R., Hopkins, C. R., Brogan, J. T., Conn, P. J., & Lindsley, C. W. (2011) · Biochemistry · doi:10.1021/bi200129s · Cited by 153
“Both the DFB (4–6) and CDPPB series (8) bind at the MPEP (3) allosteric site, whereas CPPHA (7) binds at a second, non-MPEP site.”
BackgroundFlexibility and small pockets at protein–protein interfaces: New insights into druggability
Jubb, H., Blundell, T. L., & Ascher, D. B. (2015) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2015.01.009 · Cited by 155
“Using criteria derived from retrospective analyses of successful drugs, proteineprotein interaction sites have historically been described as undruggable (Hopkins and Groom, 2002).”
BackgroundLi, Y., Li, X. X., Hong, J. J., Wang, Y., Fu, J., Yang, H. J., Yu, C. Y., Li, F., Hu, J., Xue, W., et al. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bby130 · Cited by 163
“Intensive drug discovery effort [1–6] has led to the clinical trials of hundreds of new targets [7].”
InfluentialExploitation of silicon medicinal chemistry in drug discovery
MILLS, J. S., & Showell, G. A. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.9.1149 · Cited by 169
“Proteases are well-recognised as a significant component of the drugable genome [4].”
BackgroundStructure-based systems biology for analyzing off-target binding
Xie, L., Xie, L., & Bourne, P. E. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.01.004 · Cited by 166
“Moreover, clustering proteins into target families has been applied extensively in modern drug discovery [32] to facilitate lead discovery [33].”
BackgroundOh, S., & Park, S. B. (2011) · Chemical Communications · doi:10.1039/c1cc14042f · Cited by 155
Editorial focus: understanding off-target effects as the key to successful RNAi therapy
Bartoszewski, R., & Sikorski, A. F. (2019) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-019-0196-3 · Cited by 147
Chemo- and site-selective derivatizations of natural products enabling biological studies
Robles, O., & Romo, D. (2014) · Nat. Prod. Rep. · doi:10.1039/c3np70087a · Cited by 154
Kim, H., Sohn, K.-M., Shy, M. E., Krajewski, K. M., Hwang, M., Park, J.-H., Jang, S.-Y., Won, H., Choi, B., Hong, S. H., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519529 · Cited by 154
“Indeed, the PRPS1 gene, along with other PRPS family genes, has been included in the part of the human genome thought to offer opportunities for drug therapy.(16) In summary, we found that missense mutations in the PRPS1 gene cause a syndromic form of peripheral neuropathy associated with sensorineural hearing loss an…”
BackgroundPeters, J., Schnider, P., Mattei, P., & Kansy, M. (2009) · ChemMedChem · doi:10.1002/cmdc.200800411 · Cited by 150
Analysis of multiple compound–protein interactions reveals novel bioactive molecules
Yabuuchi, H., Niijima, S., Takematsu, H., Ida, T., Hirokawa, T., Hara, T., Ogawa, T., Minowa, Y., Tsujimoto, G., & Okuno, Y. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.5 · Cited by 157
“We chose GPCRs, important pharmaceutical targets (Hopkins and Groom, 2002), as our first target proteins for virtual ligand screening.”
BackgroundOhuchi, S. P. (2012) · BioResearch open access · doi:10.1089/biores.2012.0253 · Cited by 152
“Varieties of transmembrane proteins, including G proteincoupled receptors, receptor kinases, ion channels, are important targets for the development of molecular target drugs.(35,36) Unfortunately, these proteins are usually difficult for the purification in their native conformations, and thus, Cell-SELEX is an attra…”
BackgroundThe Eyes Absent proteins in development and disease
Tadjuidje, E., & Hegde, R. S. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1144-9 · Cited by 160
Reverse Docking: A Powerful Tool for Drug Repositioning and Drug Rescue
Kharkar, P. S., Warrier, S., & Gaud, R. S. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.13.207 · Cited by 144
Saez-Rodriguez, J., Alexopoulos, L. G., Zhang, M., Morris, M. K., Lauffenburger, D. A., & Sorger, P. K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4453 · Cited by 147
“Our use of kinase inhibitors and phospho-protein antibodies naturally focused the analysis on the druggable kinome (24) but similar analysis with other classes of drugs and signaling proteins is also possible.”
Strategies for quality control of Chinese medicines
Li, S., Zhao, J., & Yang, B. (2010) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2010.12.011 · Cited by 149
Drug-Induced Regulation of Target Expression
Iskar, M., Campillos, M., Kuhn, M., Jensen, L. J., van Noort, V., & Bork, P. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000925 · Cited by 142
“Although drugs can perturb biological systems by interacting with different types of biomolecules [2], analysis of successful drugs has shown that generally they bind and alter the activity of proteins (so called drug targets).”
BackgroundBauer, R. A., Wurst, J. M., & Tan, D. S. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.02.001 · Cited by 148
“Accordingly, it has been estimated that only 10–14% of the proteins encoded in the human genome are ‘druggable’ using existing druglike molecules [3].”
Feng, Z., Wang, H., Chen, X., & Xu, B. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b07147 · Cited by 148
G Protein Selectivity Is Regulated by Multiple Intracellular Regions of GPCRs
Wong, S. K.-F. (2003) · Neurosignals · doi:10.1159/000068914 · Cited by 143
Membrane Protein Simulations Using AMBER Force Field and Berger Lipid Parameters
Cordomí, A., Caltabiano, G., & Pardo, L. (2012) · Journal of Chemical Theory and Computation · doi:10.1021/ct200491c · Cited by 147
Properties of Protein Drug Target Classes
Bull, S. C., & Doig, A. J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0117955 · Cited by 135
“The vast majority of the targets of approved drugs are proteins [1,2].”
BackgroundInfluentialKim, H. J., Howell, S. C., Horn, W. D. V., Jeon, Y. H., & Sanders, C. R. (2009) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2009.07.002 · Cited by 156
Targeting cell signaling pathways for drug discovery: An old lock needs a new key
Aggarwal, B. B., Sethi, G., Baladandayuthapani, V., Krishnan, S., & Shishodia, S. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21500 · Cited by 155
Totzke, J., Gurbani, D., Raphemot, R., Hughes, P. F., Bodoor, K., Carlson, D. A., Loiselle, D. R., Bera, A. K., Eibschutz, L. S., Perkins, M. M., et al. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.07.011 · Cited by 157
Characterization of therapeutic oligonucleotides by liquid chromatography
Goyon, A., Yehl, P., & Zhang, K. (2020) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2020.113105 · Cited by 152
Ratni, H., Scalco, R., & Stephan, A. H. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00659 · Cited by 153
Target assessment for antiparasitic drug discovery
Frearson, J. A., Wyatt, P. G., Gilbert, I. H., & Fairlamb, A. H. (2007) · Trends in Parasitology · doi:10.1016/j.pt.2007.08.019 · Cited by 144
Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs
Dong, S., Rogan, S. C., & Roth, B. L. (2010) · Nature Protocols · doi:10.1038/nprot.2009.239 · Cited by 156
“Aberrations in GPCR activity contribute to many human diseases, and most approved drugs exert their therapeutic effect by modulating GPCR activit”
BackgroundA novel inert crystal delivery medium for serial femtosecond crystallography
Conrad, C. E., Basu, S., James, D., Wang, D., Schaffer, A., Roy-Chowdhury, S., Zatsepin, N. A., Aquila, A., Coe, J. D., Gati, C., et al. (2015) · IUCrJ · doi:10.1107/s2052252515009811 · Cited by 143
“Membrane proteins are an important class of proteins that are of very high relevance in biology, compromising 60% of all current drug targets (Hopkins & Groom, 2002).”
BackgroundUrs, N. M., Gee, S. M., Pack, T. F., McCorvy, J. D., Evron, T., Snyder, J. C., Yang, X., Rodriguiz, R. M., Borrelli, E., Wetsel, W. C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614347113 · Cited by 159
“9967; genotype × treatment interaction, F(1, 480) = 3.”
BackgroundMethodInfluentialGenetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy
Suzuki, N., Nishiyama, A., Warita, H., & Aoki, M. (2022) · Journal of Human Genetics · doi:10.1038/s10038-022-01055-8 · Cited by 158
Wood, C., Williams, C., & Waldron, G. J. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03064-8 · Cited by 143
Berger, A. B., Vitorino, P. M., & Bogyo, M. S. (2004) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200404060-00004 · Cited by 165
Eldik, L. J. V., Thompson, W. L., Ranaivo, H. R., Behanna, H. A., & Watterson, D. M. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(07)82015-0 · Cited by 152
Global Phenotypic Screening for Antimalarials
Guiguemde, W. A., Shelat, A. A., Garcia-Bustos, J., Diagana, T. T., Gamo, F., & Guy, R. K. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.01.004 · Cited by 143
“…organisms, using the reasonable assumption that enzymes, receptors, and channels are the most likely targets for small molecules leads to the logical conclusion that the number of tractable essential targets for malaria probably is around 100 to 200 (Hopkins and Groom, 2002; Landry and Gies, 2008).”
Background‘Metabolite-likeness’ as a criterion in the design and selection of pharmaceutical drug libraries
Dobson, P. D., Patel, Y., & Kell, D. B. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.10.011 · Cited by 145
DRUG TARGET PREDICTIONS BASED ON HETEROGENEOUS GRAPH INFERENCE
Wang, W., Yang, S., & Li, J. (2012) · Biocomputing 2013 · doi:10.1142/9789814447973_0006 · Cited by 141
Wainwright, M. S., Rossi, J., Schavocky, J., Crawford, S., Steinhorn, D., Velentza, A. V., Zasadzki, M., Shirinsky, V., Jia, Y., Haiech, J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1031595100 · Cited by 144
Drug Design—Past, Present, Future
Doytchinova, I. (2022) · Molecules · doi:10.3390/molecules27051496 · Cited by 119
“Of the 20,000 protein-coding genes in the human genome, about 3 000 have been estimated to be part of the so-called druggable genome or druggable proteins [27].”
BackgroundThe design, structures and therapeutic potential of protein epitope mimetics
Robinson, J. A., DeMarco, S. T., Gombert, F. O., Moehle, K., & Obrecht, D. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.07.008 · Cited by 157
Identification of DHODH as a therapeutic target in small cell lung cancer
Li, L., Ng, S. R., Colón, C. I., Drapkin, B. J., Hsu, P. P., Li, Z., Nabel, C. S., Lewis, C. A., Romero, R., Mercer, K. L., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw7852 · Cited by 146
Memory Enhancement by Targeting Cdk5 Regulation of NR2B
Plattner, F., Hernández, A., Kistler, T. M., Pozo, K., Zhong, P., Yuen, E. Y., Tan, C., Hawasli, A. H., Cooke, S. F., Nishi, A., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.022 · Cited by 135
“Drug target pool algorithms such as the “rule of five” (Lipinski, 2000) and “the druggable genome” (Hopkins and Groom, 2002) have been used in an effort to facilitate the discovery of small molecules of high specificity for oral delivery.”
Background18F-Labeled Peptides: The Future Is Bright
Richter, S., & Wuest, F. R. (2014) · Molecules · doi:10.3390/molecules191220536 · Cited by 139
“The deciphering of the human genome led to the identification of 483 drug targets by the entrance into the new millennium and an estimation of 5000–10,000 druggable targets on the basis of disease-relevant genes in the future [1].”
BackgroundSaleh, N., Ibrahim, P., Saladino, G., Gervasio, F. L., & Clark, T. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00772 · Cited by 146
Spandl, R. J., Díaz‐Gavilán, M., O’Connell, K. M. G., Thomas, G. L., & Spring, D. R. (2008) · The Chemical Record · doi:10.1002/tcr.20144 · Cited by 158
Targeting enzyme inhibitors in drug discovery
Copeland, R. A., Harpel, M. R., & Tummino, P. J. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.7.967 · Cited by 152
A survey of yeast genomic assays for drug and target discovery
Smith, A. M., Ammar, R., Nislow, C., & Giaever, G. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.04.012 · Cited by 133
“…are selected based on several criteria including: 1) prior knowledge of a targets biological role(s) and potential for therapeutic intervention 2) proven value based on approved drugs (i.e. “me too” targets) 3) a target’s essentiality for cell growth and 4) druggability (Hopkins & Groom, 2002).”
BackgroundDesign of Cyclic Peptides That Bind Protein Surfaces with Antibody-Like Affinity
Millward, S. W., Fiacco, S. V., Austin, R. J., & Roberts, R. W. (2007) · ACS Chemical Biology · doi:10.1021/cb7001126 · Cited by 137
“A lthough networks of protein–protein interactions control function inside cells, it is increasingly clear that many of these players cannot be targeted using traditional druglike molecules (1).”
BackgroundExploring the structural origins of cryptic sites on proteins
Beglov, D., Hall, D. R., Wakefield, A. E., Luo, L., Allen, K. N., Kozakov, D., Whitty, A., & Vajda, S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711490115 · Cited by 134
“Many biologically relevant drug targets lack appropriately sized pockets in their unbound structures to support the strong binding of drug-sized ligands (3, 7).”
BackgroundPan-cancer proteogenomics expands the landscape of therapeutic targets
Savage, S. R., Yi, X., Lei, J. T., Wen, B., Zhao, H., Liao, Y., Jaehnig, E. J., Somes, L. K., Shafer, P. W., Lee, T. D., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.039 · Cited by 152
Qin, Y., Verdegaal, E. M. E., Siderius, M. H., Bebelman, J. P., Smit, M. J., Leurs, R., Willemze, R., Tensen, C. P., & Osanto, S. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00781.x · Cited by 154
“To date, more than 30% of the presently effective drugs target are GPCRs (Hopkins and Groom, 2002; Pierce et al., 2002; Schlyer and Horuk, 2006).”
BackgroundDrug target miRNAs: chances and challenges
Schmidt, M. F. (2014) · Trends in biotechnology · doi:10.1016/j.tibtech.2014.09.002 · Cited by 145
Hudson, B. D., Tikhonova, I. G., Pandey, S. K., Ulven, T., & Milligan, G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.396259 · Cited by 134
“2 (1) and because of their contribution to the control of key physiological systems they are the most targeted group of proteins for the development of small molecule therapeutic medicines (2-3).”
Bioinformatics in translational drug discovery
Wooller, S. K., Benstead-Hume, G., Chen, X., Ali, Y., & Pearl, F. M. G. (2017) · Bioscience Reports · doi:10.1042/bsr20160180 · Cited by 147
Amplifying gene expression with RNA-targeted therapeutics
Khorkova, O., Stahl, J., Joji, A., Volmar, C., & Wahlestedt, C. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00704-7 · Cited by 141
“As described in the following sections, besides the relatively well-studied regulatory proteins, translation efficiency can be affected by mRNA structural features that can be roughly divided into two types: (1) linear (such as 5′ caps, short upstream open reading frames (uORFs) located in 5′ UTRs, ‘toxic exons’ or po…”
InfluentialNatural antisense and noncoding RNA transcripts as potential drug targets
Wahlestedt, C. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.04.013 · Cited by 145
Juliano, R. L., Ming, X., Carver, K., & Laing, B. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0463 · Cited by 128
“Molecules that act on GPCRs comprise approximately 40% of all clinically utilized drugs while GPCRs may account for 28% of the ‘‘druggable genome’’ (Hopkins and Groom, 2002; Filmore, 2004).”
BackgroundDrewry, D. H., & Macarrón, R. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.03.024 · Cited by 145
Quevedo, C. E., Cruz-Migoni, A., Bery, N., Miller, A., Tanaka, T., Petch, D., Bataille, C. J. R., Lee, L. Y. W., Fallon, P. S., Tulmin, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05707-2 · Cited by 130
Huang, J. X., Bishop‐Hurley, S. L., & Cooper, M. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00567-12 · Cited by 159
“, nM affinity) candidates suitable for therapeutic development within a much faster timescale than that achievable for small molecules (52).”
BackgroundA crystal clear solution for determining G-protein-coupled receptor structures
Tate, C. G. (2012) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2012.06.003 · Cited by 133
Shi, S.-Y., Zhang, Y., Jiang, X., Chen, X.-Q., Huang, K.-L., Zhou, H., & Jiang, X. (2009) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2009.03.009 · Cited by 134
Lankatillake, C., Luo, S., Flavel, M., Lenon, G. B., Gill, H. S., Huynh, T. T., & Dias, D. A. (2021) · Plant Methods · doi:10.1186/s13007-020-00702-5 · Cited by 149
Chemoproteomics and Chemical Probes for Target Discovery
Drewes, G., & Knapp, S. (2018) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.06.008 · Cited by 132
Protein–protein interactions as druggable targets: recent technological advances
Higueruelo, A. P., Jubb, H. C., & Blundell, T. L. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.05.009 · Cited by 142
Target Validation: Linking Target and Chemical Properties to Desired Product Profile
Wyatt, P. G., Gilbert, I. H., Read, K. D., & Fairlamb, A. H. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611795429185 · Cited by 131
Metadata
- Authors
- Hopkins, A. L., & Groom, C. R.
- Affiliations
- Pfizer (United Kingdom) (GB)
- Corresponding author
- Groom, Colin R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-09
- Volume
- 1
- Issue
- 9
- Pages
- 727-730
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2074370114
- Cited by
- 3,305
- References
- 16
- Citations by year
- 2026: 91 · 2025: 113 · 2024: 131 · 2023: 116 · 2022: 155 · 2021: 150 · 2020: 144 · 2019: 147 · 2018: 136 · 2017: 132 · 2016: 144 · 2015: 182 · 2014: 162 · 2013: 161 · 2012: 212
- FWCI
- 70.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Science, Research, and Medicine
- Keywords
- druggable genome, therapeutic target, molecular targets, target identification
- MeSH terms
- Biological Availability, Chemistry, Pharmaceutical, Humans, Molecular Biology, Pharmacokinetics, Genome, Human
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.